The Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, United States.
Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
Front Immunol. 2021 Sep 13;12:714177. doi: 10.3389/fimmu.2021.714177. eCollection 2021.
Sepsis continues to be a major cause of morbidity, mortality, and post-recovery disability in patients with a wide range of non-infectious and infectious inflammatory disorders, including COVID-19. The clinical onset of sepsis is often marked by the explosive release into the extracellular fluids of a multiplicity of host-derived cytokines and other pro-inflammatory hormone-like messengers from endogenous sources ("cytokine storm"). In patients with sepsis, therapies to counter the pro-inflammatory torrent, even when administered early, typically fall short. The major focus of our proposed essay is to promote pre-clinical studies with hCG (human chorionic gonadotropin) as a potential anti-inflammatory therapy for sepsis.
脓毒症仍然是广泛的非传染性和传染性炎症性疾病患者发病率、死亡率和康复后残疾的主要原因,包括 COVID-19。脓毒症的临床发作通常以大量宿主来源的细胞因子和其他内源性炎症激素样信使从细胞外液中爆发为标志(“细胞因子风暴”)。在脓毒症患者中,即使早期给予对抗促炎洪流的治疗,通常也不够。我们提出的论文的主要重点是促进 hCG(人绒毛膜促性腺激素)作为脓毒症潜在抗炎治疗的临床前研究。